María Paniagua-García

Dr. María Paniagua-García

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2023 in eClinicalMedicine
Verified
Journal Article
Open access
SPSalvador Pérez-Galera
Salvador Pérez-Galera
JBJose M Bravo-Ferrer
Jose M Bravo-Ferrer
MPMaría Paniagua-García
María Paniagua-García
TKTomislav Kostyanev
Tomislav Kostyanev
MKMarlieke E A de Kraker
Marlieke E A de Kraker
CTCombacte-Care-Eureca Team
Combacte-Care-Eureca Team
Data on risk factors for carbapenem-resistant Enterobacterales (CRE) with wider applicability are needed to inform preventive measures and efficient design of randomised trials. An international matched case-control-control study was performed in 50 hospitals with high CRE incidence from March 2016 to November 2018 to investigate different aspects of infections caused by CRE (NCT02709408). Cases were patients with complicated urinary tract infection (cUTI), complicated intraabdominal (cIAI), pneumonia or bacteraemia from other sources (BSI-OS) due to CRE; control groups were patients with infection caused by carbapenem-susceptible Enterobacterales (CSE), and by non-infected patients, respectively. Matching criteria included type of infection for CSE group, ward and duration of hospital admission. Conditional logistic regression was used to identify risk factors. Overall, 235 CRE case patients, 235 CSE controls and 705 non-infected controls were included. The CRE infections were cUTI (133, 56.7%), pneumonia (44, 18.7%), cIAI and BSI-OS (29, 12.3% each). Carbapenemase genes were found in 228 isolates: OXA-48/like, 112 (47.6%), KPC, 84 (35.7%), and metallo-β-lactamases, 44 (18.7%); 13 produced two. The risk factors for CRE infection in both type of controls were (adjusted OR for CSE controls; 95% CI; p value) previous colonisation/infection by CRE (6.94; 2.74-15.53; <0.001), urinary catheter (1.78; 1.03-3.07; 0.038) and exposure to broad spectrum antibiotics, as categorical (2.20; 1.25-3.88; 0.006) and time-dependent (1.04 per day; 1.00-1.07; 0.014); chronic renal failure (2.81; 1.40-5.64; 0.004) and admission from home (0.44; 0.23-0.85; 0.014) were significant only for CSE controls. Subgroup analyses provided similar results. The main risk factors for CRE infections in hospitals with high incidence included previous colonization, urinary catheter and exposure to broad spectrum antibiotics. The study was funded by the Innovative Medicines Initiative Joint Undertaking (https://www.imi.europa.eu/) under Grant Agreement No. 115620 (COMBACTE-CARE).

3 July 2025 in eClinicalMedicine
Verified
Journal Article
Open access
MPMaría Paniagua-García
María Paniagua-García
AGAna Belén Guisado-Gil
Ana Belén Guisado-Gil
JGJosé Molina Gil-Bermejo
José Molina Gil-Bermejo
GPGermán Peñalva
Germán Peñalva
RÁRocío Álvarez-Marín
Rocío Álvarez-Marín
JCJosé M. Cisneros
José M. Cisneros
Solid organ transplant recipients (SOTr) are at high risk of infectious complications, and effective antimicrobial stewardship (AMS) programmes need to be developed. We aimed to review the available evidence on the effectiveness and safety of different strategies to optimise antibiotic use in SOTr. In our systematic review and meta-analyses, we searched MEDLINE (via PubMed), EMBASE, and SCOPUS for original research articles published up to 06 March 2025. Studies with a control group evaluating different strategies to optimise antimicrobial use in adult SOTr were included. The outcomes assessed were mortality, transplant-related complications, infectious outcomes, development of antimicrobial resistance, antimicrobial consumption, hospital related variables, and antimicrobial toxicities. A risk-of-bias assessment was performed using the Cochrane EPOC group's criteria. Data from included studies were pooled in meta-analyses if three or more studies had the same type of intervention and comparison group and reported sufficient data on infection outcomes to be combined. Meta-analyses were performed using a random-effects model and the inverse variance method with the I2 statistic to test for inconsistency between studies. Sensitivity analyses were also evaluated. This study follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PROSPERO ID: CRD42024554606. Of the 4050 articles identified, 34 studies met the inclusion criteria. Seventeen studies addressed perioperative antimicrobial prophylaxis (seven of which evaluated specifically duration of antimicrobial prophylaxis), two reported information about decolonisation strategies, three addressed duration of antimicrobial treatment as target therapy, one evaluated antibiotic oral step-down strategy, and six reported the impact of AMS implementation approach on SOTr. The other five studies evaluated specific targeted prophylaxis. All the studies had a moderate or high risk of bias. The meta-analysis of three studies on the effect of AMS programmes showed that this intervention may reduce the rate of surgical site infections (OR 0·57, 95% CI 0·35–0·94). For perioperative antimicrobial prophylaxis, the meta-analysis of six trials showed results in favour of prophylaxis in terms of reducing surgical site infections (risk ratio 1·93, 95% CI 1·14–3·27) in kidney SOTr, but prolonging prophylaxis beyond 24 h was not associated with improved SSI rates (RR 0·87, 95% CI 0·51–1·48). Regarding the duration of antimicrobial treatment for uncomplicated graft-related infections (liver and kidney SOTr), the meta-analyses found no difference in terms of recurrence between short and long antimicrobial regimens (0·86, 95% CI 0·55–1·34). The four meta-analyses had low heterogeneity between studies. Strategies to optimise antimicrobial use are safe, with no negative impact on mortality or transplant-related complications, and appear to improve some clinical outcomes in SOTr, particularly when using perioperative antimicrobial prophylaxis in kidney SOTr and when implementing AMS programmes. No difference in the rate of surgical site infection was found between short and extended duration of antimicrobial prophylaxis for kidney and liver SOTr. This suggests that a shorter duration of antimicrobial surgical prophylaxis may be safe for transplant recipients. Short courses of antibiotics were not associated with an increased rate of relapses for uncomplicated graft infections, according to observational studies pooled in our meta-analysis. However, further high-quality clinical trials are needed to better understand the effects of these strategies in SOTr and to design optimal AMS interventions in this population. This study was supported by the 10.13039/501100004587 Instituto de Salud Carlos III ( 10.13039/501100004587 ISCIII , reference ICI21/00075) and the 10.13039/501100023961 Centro de Investigación Biomédica en de Enfermedades Infecciosas ( 10.13039/501100023961 CIBERINFEC , CB21/13/00006), 10.13039/501100004587 ISCIII , 10.13039/501100004837 Ministerio de Ciencia e Innovación .

5 March 2019 in Medicina Clinica
Verified
Journal Article
Closed access
MPMaría Paniagua-García
María Paniagua-García
ZPZaira R. Palacios-Baena
Zaira R. Palacios-Baena
MLMaría Dolores del Toro López
María Dolores del Toro López

Verified
Journal Article
Open access
PDF file
CCCebrero Cangueiro
Cebrero Cangueiro
SESoraya Herrera Espejo
Soraya Herrera Espejo
MPMaría Paniagua-García
María Paniagua-García
GLGema Labrador-Herrera
Gema Labrador-Herrera
JCJosé M. Cisneros
José M. Cisneros
María Eugenia Pachón IbáñezMaría Eugenia Pachón Ibáñez
María Eugenia Pachón Ibáñez
We evaluated the efficacy of the adoptive transfer of memory B, CD4+, and CD8+ T lymphocytes compared with sulbactam and tigecycline in an experimental murine pneumonia model by two multidrug-resistant Acinetobacter baumannii strains, colistin-susceptible AbCS01 and colistin-resistant AbCR17. Pharmacodynamically optimized antimicrobial dosages were administered for 72 h, and intravenous administration of 2 × 106 of each of the memory cells in a single dose 30 min post-infection. Bacterial lung and blood counts and mortality rates were analyzed. Results showed that a single dose of memory B or CD4+ T cells was as effective as sulbactam in terms of bacterial clearance from the lungs and blood compared with the untreated mice or the tigecycline-treated mice inoculated with the AbCS01 strain. In the pneumonia model by AbCR17, a single dose of memory B or CD4+ T cells also reduced the bacterial load in the lungs compared with both antibiotic groups and was more efficacious than tigecycline in terms of blood clearance. Regarding survival, the adoptive transfer of memory B or CD4+ T cells was as effective as three days of sulbactam treatment for both strains. These data suggest that adoptive memory cell transfer could be a new effective treatment of multidrug-resistant A. baumannii infections.

3 July 2024 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
JMJavier Martín-Escolano
Javier Martín-Escolano
SSSonsoles Salto-Alejandre
Sonsoles Salto-Alejandre
CICarmen Infante-Domínguez
Carmen Infante-Domínguez
MCMarta Carretero-Ledesma
Marta Carretero-Ledesma
NMNatalia Maldonado-Lizarazo
Natalia Maldonado-Lizarazo
MAManuela Aguilar-Guisado
Manuela Aguilar-Guisado
Objectives: Patients with haematologic malignancies (HM) COVID-19 have more severe disease, with increased risk of mortality. Therefore, this study aimed to evaluate the effect of SARS-CoV-2 RNAemia and the specific humoral immune responses on the clinical outcomes of patients with HM and COVID-19. Methods: Interferon-alpha/gamma alpha / gamma (IFN- alpha /IFN- gamma ) serum levels, neutralizing antibodies and RNAemia at COVID-19 diagnosis, and persistent RNAemia during the follow-up were evaluated. Results: Overall, 63 (58.9%) out of 107 patients had RNAemia, which was persistent in 26 (41.3%) patients. RNAemia at diagnosis and persistent RNAemia were associated with the need for high-flow nasal oxygen therapy during admission. Persistent RNAemia, age > 70 years, and CURB-65 score >= 2 in patients with pneumonia were associated with increased 90-day mortality ( P = 0.009, P = 0.030 and P = 0.001, respectively). The 90-day overall survival was lower ( P = 0.006) in patients with persistent RNAemia. In addition, dexamethasone administration was associated with a COVID-19 episode with persistent RNAemia. Conclusion: Our results suggest that in patients with HM, RNAemia at the time of COVID-19 diagnosis and during the follow-up can be used to stratify patients with HM according to their clinical evolution and to guide clinical decisions tailored to the specific needs of each patient.

23 June 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
MPMaría Paniagua-García
María Paniagua-García
JBJosé Manuel Bernal-Aznar
José Manuel Bernal-Aznar
EGEffrossyni Gkrania-Klotsas
Effrossyni Gkrania-Klotsas
ISIsobel Soper
Isobel Soper
MMMaría Lluisa Pedro-Botet Montoya
María Lluisa Pedro-Botet Montoya
ARAlberto Romero-Palacios
Alberto Romero-Palacios
Background: Campylobacter spp bloodstream infections (BSIs) are an emerging clinical challenge, yet information on their clinical features remains limited. We aimed to evaluate their differential clinical characteristics and outcomes in immunocompetent (IC) and immunodeficient (ID) patients. Methods: A multicenter, multinational, retrospective cohort study of consecutive Campylobacter spp BSIs between 2009 and 2024 was carried out. Demographics, Charlson comorbidity index, types of immunodeficiencies, clinical characteristics, and antimicrobial susceptibility were analyzed. The primary outcomes were relapse or reinfection and death (all-cause mortality outcome). Results: A total of 261 episodes were included, 89 (34.1%) in IC and 172 (65.9%) in ID patients. Among the 172 ID patients, 104 (60.5%) and 68 (39.5%) had humoral or nonhumoral immunodeficiency (primary or secondary), and 42 (24.4%) had primary immunodeficiencies (PIDs). Patients with humoral immunodeficiency (humoral-ID patients) were younger (median age, 40 years [interquartile range, 23–66 years]), had lower Charlson comorbidity indexes (2 [1–5]), and had a higher frequency of previous Campylobacter spp infection. Resistance rates to fluoroquinolones (75%) and macrolides (14.5%) were high. BSI relapse or reinfection occurred in 21 (8.0%) patients, mostly humoral-ID patients (n = 19 [18.3%]), 11 (57.9%) of whom had PID. Death occurred with 30 days (all-cause mortality outcome) in 26 patients (9.9%) across the entire cohort; the 30-day mortality rate was lower in humoral-ID (n = 5 [4.8%]) than in IC (n = 12 [13.5%]; P = .05) patients. Conclusions: Humoral-ID patients and those with Campylobacter spp BSI were younger and had fewer comorbid conditions, and Campylobacter coli was the most frequent species. Relapse or reinfection was common in humoral-ID patients, particularly those with PID. The antimicrobial resistance in C coli and Campylobacter jejuni represents a clinical concern.